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Soutcome, a recurrence rate of 0% to 4.5% has been reported
in a thoracoscopic series (Table 1) with variable follow-up
(14.5-65 months). Our data agree with the 1.3% recurrence
rate; the single relapse observed was in a type-C thymic tu-
mor, the histology of which was defined only after surgery.
No clear evidence of a violation of oncologic principles dur-
ing the surgical procedure was recorded in this patient. De-
spite adjuvant treatment, the patient developed a diffuse
intrathoracic recurrence, surviving 52months after the oper-
ation. Cheng and coworkers25 and Pennathur and col-
leagues18 compared VATS and transsternal approaches for
thymoma in a small series and reported no significant differ-
ence in recurrence rate or overall survival between the 2
groups. Although encouraging, these results cannot be con-
sidered definitive, because the indolent nature of thymoma
requires longer follow-up data, such as 10 years, to deter-
mine the oncologic outcome of thoracoscopic thymectomy.
The current study had some limitations—in particular, its
nonrandomized, retrospective, and multi-institutional de-
sign. In addition, although the follow-up was longer than
that of most previous studies, it was still inadequate to allow
a definitive conclusion on oncologic outcome. In summary,
robotic-assisted thoracoscopic thymectomy for early-stage
thymomas can be performed safely and efficiently from
a technical point of view. In addition to the advantages of
the minimally invasive approach (short hospital length of
stay, excellent cosmetics, and low morbidity), the increased
visualization and instrument dexterity afforded by robotic
technology provides further benefit over conventional thor-
acoscopy. Our data on a relatively large number of patients
are encouraging; however, thymoma resection with conven-
tional or robot-assisted thoracoscopy remains under evalu-
ation, because long-term oncologic results are lacking.References
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Dr Cameron D. Wright (Boston, Mass). I would like to thank
Dr Marulli and his colleagues for a very well-presented series with
outstanding results. I appreciate receiving the manuscript for my
timely review.
Dr Marulli and his colleagues have described an early analysis
of a large series of patients with early-stage thymoma treated with
robotic thymectomy with excellent perioperative results from 4
large centers. The operating room times were quite reasonable,
complications low and reasonable and not really related to the ap-
proach, the median length of stay was short at 3 days, and the re-
currence rate observed was quite low. The one caveat of the series
is that the median follow-up is relatively short at 3.5 years. There’s
no question that there was very careful and prudent case selection,
and prudent and careful intraoperative operating room judgment
exercised, with a no-touch and en bloc technique as well as with
total thymectomy. An important caveat is that most recurrences
of encapsulated early-stage thymomas occur between 5 years
and 10 years in all the series that have been reported to date. Ob-
viously, your follow-up is short and, as you appropriately say, your
conclusions are tentative at this point; however, I expect the resultsgery c November 2012
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Sin the end to be equivalent to the open approach, and I look forward
to your publication in another 5 to 10 years describing those results
with your excellent judgment and excellent technical skills.
I have just a couple of comments. Just to confirm, because it
wasn’t described in your paper, were, indeed, all resections an
R0 resection?
Dr Marulli. In our opinion, the resections were all R0 resec-
tions. All the specimens were evaluated macroscopically and mi-
croscopically after resection.
DrWright. You didn’t describe in your manuscript the method
of follow-up, and obviously clinical follow-up by calling their phy-
sician, a telephone call to the patient, or a chest radiograph are all
inadequate. The only follow-up that is really adequate for patients
with thymoma is periodic computed tomography (CT) scans to
look at the mediastinum and the pleural space. Did all of your pa-
tients have follow-up CT scans, what was the follow-up protocol,
and were there any patients lost to follow-up or not put on a CT
periodic surveillance protocol?
Dr Marulli. Obviously, these patients were carefully followed
up. Usually, our protocol is to do a clinical in-hospital evaluation
of the patient at least every 6 months during the first 3 years,
with a CT scan at least every year.Moreover, regarding the patients
with MG, all these patients are followed up by a team of neurolo-
gists who have a close connection with us, and then in case of var-
iation of clinical status, like a worsening of MG, they are referred
to us to evaluate the possible presence of a recurrence. But in all
patients, we do a CT scan at least each year.
Dr Joseph B. Shrager (Stanford, Calif). So all of these patients
had a CT scan?
Dr Marulli. Yes.
Dr Shrager. Within a year of the study data collection?
Dr Marulli. Yes. The last follow-up was last March.
Dr Wright. The last query is the patient who had a diffuse in-
trathoracic recurrence. It makesme concerned that therewas a cap-
sular violation. I realize it was a type C patient, but in looking
back, were there reasons why that patient would recur diffusely in-
trathoracically so early?
DrMarulli. This patient was in the group at Innsbruck and was
not a stage I but was a stage IIB patient. We asked to reevaluate the
histology of this patient, but I have no reply at this moment. It is
possible that the capsule was breached. The patient did adjuvant
radiotherapy, but he relapsed intrathoracically with both pleural
and intrapulmonary metastases. I don’t know if the patient is really
type C, but we are evaluating that.
Dr Wright. Thank you very much.
Dr Robert J. Cerfolio (Birmingham, Ala). Excellent presenta-
tion. I have some questions about the technical details. We have
a paper coming out in the Journal of Thoracic and Cardiovascular
Surgery in a month or 2 months, I think, about 160 robotic medi-
astinal tumors, and a lot of them are thymectomies. I teach a course
on this issue and I tell everybody that you should go from the right
side, and the reason I prefer the right, and I don’t know if you can
go back to that picture of yours where you have the one thing just
under the left breast, is you’re very close to the heart, and in the
United States we know of at least 4 patients who had attempted ro-
botic thymectomies in inexperienced hands from the left side and
the heart was lacerated, the pericardium was injured, and a few of
these patients did not do well. So I feel strongly that we, especiallyThe Journal of Thoracic and Carin the beginning, should be going from the right side and not the
left. However, I do agree that you can see the right phrenic nerve
better from the left chest.
So it would be great if you could educate us on how you’re doing
it so safely from the left and maybe you can instill your experience
and wisdom to us sowhen we teach inexperienced teams how to do
it, we can do it safer from the left. You make the middle incision
first, correct? Then put the camera in, insufflate carbon dioxide,
you do that first. What port do you put in second? Do you put in
the upper axillary port second and then push the heart down as
you put in the third and final lower port?What do you do if the heart
is big and it’s in the way? Teach us some technical tricks.
Dr Marulli. Most patients were operated by the left-sided ap-
proach. Only 5 patients had a bilateral approach. We don’t feel
that it’s difficult to see the right phrenic nerve, because if you
open the pleura on the—
Dr Cerfolio. No, no. I understand you can see the right phrenic
nerve very easily from the left and there is often a tongue of thymus
near the aortopulmonary window that is much easier to get out
from the left rather than the right. That’s not my question. I agree
that is the advantage to being on the left. That’s not what I’m ask-
ing. What I’m asking is, there have been injuries to the heart being
on the left side, and as someone who is training others on this, and
we will be submitting a manuscript on this, even with a left-sided
thymoma, we are going on the right. I’m asking you to tell us how
you’re avoiding the heart with the sequence of your trocar place-
ment and other technical details to make it safe in inexperienced
hands. I want you to educate us on your technique because it seems
to be very safe in your hands and not in ours or others. That’s the
question.
DrMarulli.Wefirst insert the trocar for the camera port follow-
ing the lateral aspect of the chest wall to avoid the heart, then we
insufflate carbon dioxide, and usually this gives us enough space to
place the parasternal trocar without risks of heart injury. Some-
times, for more safety, we use the port at the spot on the third in-
tercostal space going over the heart and taking it down with
a cadiere or spatula. By this way, I think it’s not dangerous.
Dr Cerfolio. So you’re turning your carbon dioxide up, you’re
putting a spatula to hold the heart down, and then putting that port
in last, using a needle to find it. I’ve tried all those things. I still
think we should be on the right, at least to start. I think it’s safer
on the right.
Dr Wright. Let me just jump up and defend the poor author
here. He has an outstanding series of 80 patients with no heart in-
juries, Cerf. He’s doing it theway he likes to do it. We all know that
there’s a controversy of right versus left, and there’s pros and cons
to each approach, but I would say that his approach is certainly
valid.
Dr Cerfolio. I agree. I didn’t say it wasn’t. Maybe you didn’t
hear me, Cam.
Dr Shrager. He said, explain how you can best do it safely.
DrCerfolio. I am happy to have someone go back to read what I
just said. I never said their technique was not safe. We have
a unique opportunity for a world-class group to educate us in
this room right now. What I said is, I think it’s safer to be on the
right for training or to start, and I stand by what I say.
Dr Jens C. Rueckert (Berlin, Germany). I would like to add
a comment. With 280 thymectomies, we have had no difficultiesdiovascular Surgery c Volume 144, Number 5 1131
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Sever with the left-sided approach. The discussion here is, again,
well, I’ll take it home because then I see it’s right to publish on
that question alone. I prepared the manuscript, including all the ar-
guments I heard during the last 15 years, very interesting argu-
ments. I heard that the right-handed surgeon could be better
coming from the right side. Maybe. But the radicality is the most
important question, and the placement of the trocars should be
learned, of course, with insufflation of carbon dioxide in the older
or bigger patient, this is correct, but radicality is better from the left
side.We include always, even in patients without thymoma, a com-
plete resection, en bloc resection, of the tissue in the aortopulmo-
nary window. This is clearly better from the left side. And the
angulation of the typical anatomic site, the anatomic landmark of
the innominate, it’s better entering the neck from the left side. There
is much more to be said. If we discuss the right side for that ap-
proach, don’t leave the room without the message: the left side.
Dr Alper Toker (Istanbul, Turkey). I would like to know what
your attitude is toward lymph node dissection, especially in type C
patients.1132 The Journal of Thoracic and Cardiovascular SurDr Marulli. Obviously, in this case, the histology was known
only after the resection. So this patient was a surprise for us. In
this case, only adjuvant radiotherapy was considered for this pa-
tient. But intraoperatively, the patient had thymoma, apparently
encapsulated thymoma, so it was unknown. Usually for stage I
and stage II there is no need for lymphadenectomy.
Dr Shrager. Is there a size limit at which you would not ap-
proach a thymoma robotically? And for the audience: Is anybody
trying to do tumors that might be involving the great vessels
robotically?
Dr Marulli. The best indication is less than 3 cm. For robotic,
probably less than 5 cm.
Dr Shrager. But your mean size here was 3 cm.
Dr Marulli. Yes. We had 14 patients who had a dimension>5
cm. Only 1 was 12 cm. Most of the patients were<8 cm. If the
tumor is unilateral in the lower part of the thymus, probably resec-
tion can be safe with easy access to the contralateral mediastinum
and the neck. In these cases, you can do also a tumor>5 cm. A
good indication is less than 5 cm.gery c November 2012
